Targeting the "Undruggable" Driver Protein, KRASG12D, as Potential Therapy in Prostate Cancer

Abstract

In spite of the progress made in the development of KRAS^G12C inhibitors, there is still continued interest to develop inhibitors of other KRAS such as KRAS^G12D for the treatment of diseases, including prostate cancer, colorectal cancer, and non-small-cell lung cancer. This Patent Highlight provides exemplary compounds having activity as inhibitors of G12D mutant KRAS protein.